新型漸凍症治療方案能延長患者生存期並提升生活品質
New ALS Treatment Improves Survival and Quality of Life
對抗肌萎縮性脊髓側索硬化症（ALS）的鬥爭正進入精準醫療的新時代。
The fight against Amyotrophic Lateral Sclerosis (ALS) is entering a new era of precision medicine.
儘管尋找廣泛療法的探索仍在持續，研究人員透過專注於該疾病的特定遺傳驅動因素而獲得成功。
While the search for a universal cure continues, researchers are finding success by focusing on specific genetic drivers of the disease.
一項重大突破是Tofersen，這是專為SOD1基因突變患者設計的治療藥物。
A major breakthrough is Tofersen, a treatment specifically designed for patients with a mutation in the SOD1 gene.
與過去曾展現希望卻在大型試驗中失敗的療法（如Relyvrio）不同，Tofersen已證實具有明確的臨床益處。
Unlike past therapies that showed promise but failed in large trials, such as Relyvrio, Tofersen has demonstrated clear clinical benefits.
數據顯示，及早開始使用Tofersen可顯著減緩身體與呼吸功能下降的進程，協助許多患者更長時間維持獨立生活。
Data indicates that early initiation of Tofersen significantly slows the progression of physical and respiratory decline, helping many patients maintain their independence for longer.
這種成功凸顯了精準醫療相較於廣泛且一體適用之治療的重要性。
This success underscores the importance of precision medicine over broad, one-size-fits-all treatments.
雖然Relyvrio因在第三期臨床試驗中未能達到終點而被撤出市場，但它凸顯了ALS研究的嚴謹性。
While Relyvrio was withdrawn after failing to meet endpoints in its Phase 3 trial, it highlighted the rigorous nature of ALS research.
今天，焦點在於個人化療法、平台試驗與早期干預。
Today, the focus is on personalized therapies, platform trials, and early intervention.
就目前而言，將這些標靶藥物與多學科照護相結合，仍是管理此一複雜狀況的黃金標準，讓我們向更有效干預的未來邁進。
For now, combining these targeted medications with multidisciplinary care remains the gold standard for managing this complex condition as we move toward a future of more effective interventions.
